LLY

769.87

+0.76%↑

JNJ

155.03

+1.03%↑

ABBV

189.89

+1.42%↑

NVO

74.74

+3.06%↑

UNH

303.11

+2.59%↑

LLY

769.87

+0.76%↑

JNJ

155.03

+1.03%↑

ABBV

189.89

+1.42%↑

NVO

74.74

+3.06%↑

UNH

303.11

+2.59%↑

LLY

769.87

+0.76%↑

JNJ

155.03

+1.03%↑

ABBV

189.89

+1.42%↑

NVO

74.74

+3.06%↑

UNH

303.11

+2.59%↑

LLY

769.87

+0.76%↑

JNJ

155.03

+1.03%↑

ABBV

189.89

+1.42%↑

NVO

74.74

+3.06%↑

UNH

303.11

+2.59%↑

LLY

769.87

+0.76%↑

JNJ

155.03

+1.03%↑

ABBV

189.89

+1.42%↑

NVO

74.74

+3.06%↑

UNH

303.11

+2.59%↑

Hologic Inc

Затворен

СекторЗдравеопазване

64.32 2.11

Преглед

Промяна на цената на акция

24 ч

Текуща

Минимум

62.96

Максимум

64.57

Ключови измерители

By Trading Economics

Приходи

-218M

-17M

Продажби

-17M

1B

P/E

Средно за сектора

26.055

51.198

EPS

1.03

Марж на печалбата

-1.731

Служители

7,063

EBITDA

-359M

-7M

Препоръки

By TipRanks

Препоръки

Купи

12-месечна прогноза

+5.36% upside

Дивиденти

By Dow Jones

Следващи печалби

28.07.2025 г.

Пазарни показатели

By TradingEconomics

Пазарна капитализация

-1.1B

14B

Предишно отваряне

62.21

Предишно затваряне

64.32

Настроения в новините

By Acuity

24%

76%

56 / 380 Класиране в Healthcare

Техническа оценка

By Trading Central

Увереност

Bullish Evidence

Hologic Inc Графика

Миналото представяне не гарантира бъдещи резултати.

Свързани новини

27.05.2025 г., 18:46 ч. UTC

Значими двигатели на пазара
Придобивния, сливания и поглъщания

Hologic Shares Up Following Report of Buyout Offer From TPG, Blackstone

27.05.2025 г., 20:07 ч. UTC

Придобивния, сливания и поглъщания

Hologic Stock Is Surging. Why Shares of the MedTech Company Are Up 14%. -- Barrons.com

27.05.2025 г., 19:06 ч. UTC

Придобивния, сливания и поглъщания

Hologic Stock Is Surging. Why Shares of the MedTech Company Are Up 14%. -- Barrons.com

27.05.2025 г., 18:26 ч. UTC

Придобивния, сливания и поглъщания

Hologic Stock Is Surging. Why Shares of the MedTech Company Are Up 19%. -- Barrons.com

Сравнение с други в отрасъла

Ценова промяна

Hologic Inc Прогноза

Ценова цел

By TipRanks

5.36% нагоре

12-месечна прогноза

Среден 66.45 USD  5.36%

Висок 71 USD

Нисък 60 USD

Според 14 анализатори от Wall Street, предложили 12-месечна ценова цел за Hologic Inc през последните три месеца.

Консенсусна оценка

By TipRanks

Купи

14 ratings

5

Купи

9

Задържане

0

Продай

Техническа оценка

By Trading Central

52.69 / 58.605Подкрепа & съпротива

Краткосрочен план

Bullish Evidence

Средносрочен план

Weak Bearish Evidence

Дългосрочен план

Bearish Evidence

Настроение

By Acuity

56 / 380 Класиране в Здравеопазване

Настроения в новините

Много силни бичи доказателства

Волатилност

Под средното

Обем новини (RCV)

Над средното

Финанси

Продажбени и админисративни разходи

Оперативни разходи

Печалба преди облагане с данъци

Продажби

Разходи за продажби

Брутна печалба от продажби

Разходи за лихви по дълг

EBITDA

Оперативна печалба

$

Относно Hologic Inc

Hologic, Inc. engages in the development, manufacture, and supply of diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment worldwide. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth. The company also offers breast cancer care solutions in the areas of radiology, breast surgery, pathology, and treatment, such as 3D digital mammography systems, image analytics software, reading workstations, minimally invasive breast biopsy guidance systems, breast biopsy site markers, localization, and specimen radiology solutions; and breast conserving surgery products. In addition, it provides MyoSure Hysteroscopic Tissue Removal System for the removal of fibroids and polyps in the uterus; NovaSure Endometrial Ablation System to treat abnormal uterine bleeding; Fluent Fluid Management System that provides liquid distention during diagnostic and operative hysteroscopic procedures; Acessa ProVu system to treat various fibroids; and CoolSeal portfolio, such as bipolar vessel sealing devices. Further, it offers Horizon DXA, a dual energy X-ray system; and Fluoroscan Insight FD mini C-arm to perform minimally invasive orthopedic surgical procedures. It sells its products through direct sales, service forces, independent distributors, and sales representatives. The company was incorporated in 1985 and is headquartered in Marlborough, Massachusetts.